Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
Table 2
Oxidative stress and inflammatory profile of newly diagnosed and long-standing T2DM patients.
CSII N group
MDI3 N group
MDI4 N group
8-PGF (pg/mL)
N
Before therapy
8.11 ± 2.77
9.46 ± 0.89
10.15 ± 2.34
After therapy
6.12 ± 2.66
7.00 ± 1.93
6.70 ± 2.53
L
Before therapy
8.07 ± 2.89
8.58 ± 3.14
8.46 ± 1.75
After therapy
4.10 ± 2.93
5.17 ± 3.88
4.16 ± 2.10
TNF-α (pg/mL)
N
Before therapy
19.59 ± 4.56
18.01 ± 7.41
17.11 ± 6.32
After therapy
9.08 ± 5.14
10.26 ± 3.33
8.12 ± 5.00
L
Before therapy
13.46 ± 2.99
14.53 ± 3.23
11.65 ± 4.58
After therapy
6.08 ± 1.14
8.70 ± 2.34
6.25 ± 2.37
IL-6 (pg/mL)
N
Before therapy
4.51 ± 1.87
5.08 ± 1.12
6.08 ± 4.52
After therapy
2.17 ± 1.43
2.60 ± 0.78
2.90 ± 1.84
L
Before therapy
3.66 ± 2.19
4.12 ± 1.88
3.73 ± 2.00
After therapy
2.62 ± 2.16
4.32 ± 1.45
3.01 ± 2.55
Data are mean ± (SD). , versus the same item before therapy; versus MDI3 N group after therapy. N: newly diagnosed T2DM patients group; L: long-standing T2DM patients group.
